Search results for "Vascularization"

showing 10 items of 519 documents

HIF-1α and HIF-2α Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1α Correlates Negatively to Advanced Clinical Stage and Tumor Vascu…

2009

Abstract Purpose: Hypoxia is considered to be a major driving force behind tumor angiogenesis. The stabilization and activation at hypoxia of the hypoxia-inducible factors HIF-1α and HIF-2α and the concomitant induction of expression of vascular endothelial growth factor (VEGF) and other proangiogenic factors provide a molecular frame for hypoxia-driven tumor angiogenesis. This study has investigated how HIF and VEGF protein levels relate to each other with regard to vascularization, tumor stage, and overall survival in neuroblastoma. Experimental Design: Tissue cores taken from tumor specimens representing 93 children with neuroblastoma were arranged on a microarray and stained for HIF-1α,…

MaleVascular Endothelial Growth Factor ACD31Cancer ResearchPathologymedicine.medical_specialtyBiologyModels BiologicalNeovascularizationchemistry.chemical_compoundIn vivoNeoplasmsNeuroblastomaBasic Helix-Loop-Helix Transcription FactorsmedicineHumansHypoxiaRegulation of gene expressionNeovascularization PathologicInfantCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseGene Expression Regulation NeoplasticPlatelet Endothelial Cell Adhesion Molecule-1Vascular endothelial growth factorTreatment OutcomeHIF1AOncologychemistryChild PreschoolCancer researchFemalemedicine.symptomClinical Cancer Research
researchProduct

Crosstalk between osteoblasts and endothelial cells co-cultured on a polycaprolactone-starch scaffold and the in vitro development of vascularization.

2009

The reconstruction of bone defects based on cell-seeded constructs requires a functional microvasculature that meets the metabolic demands of the engineered tissue. Therefore, strategies that augment neovascularization need to be identified. We propose an in vitro strategy consisting of the simultaneous culture of osteoblasts and endothelial cells on a starch-based scaffold for the formation of pre-vascular structures, with the final aim of accelerating the establishment of a vascular bed in the implanted construct. Human dermal microvascular endothelial cells (HDMECs) were co-cultured with human osteoblasts (hOBs) on a 3D starch-based scaffold and after 21 days of culture HDMEC aligned and…

MaleVascular Endothelial Growth Factor ACell typeScaffoldMaterials sciencePolyestersBiophysicsConnexinNeovascularization PhysiologicBioengineering02 engineering and technologyBiomaterialsNeovascularizationDiffusion03 medical and health sciencesType IV collagenTissue engineeringOsteogenesismedicineHumansTissue engineeringBonePolymer030304 developmental biology0303 health sciencesScience & TechnologyOsteoblastsTissue ScaffoldsVascularizationEndothelial CellsStarch021001 nanoscience & nanotechnologyImmunohistochemistryCoculture TechniquesCell biologyCrosstalk (biology)Mechanics of MaterialsCeramics and Compositesmedicine.symptomCo-culture0210 nano-technologyType I collagenBiomedical engineeringBiomaterials
researchProduct

Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization

2017

We have engineered polymer-based microenvironments that promote vasculogenesis both in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly(ethyl acrylate) (PEA) triggers spontaneous organization of fibronectin (FN) into nanonetworks which provide availability of critical binding domains. Importantly, the growth factor binding (FNIII12-14) and integrin binding (FNIII9-10) regions are simultaneously available on FN fibrils assembled on PEA. This material platform promotes synergistic integrin/VEGF signalling which is highly effective for vascularization events in vitro with low concentrations of VEGF. VEGF specifically binds to FN fibrils on PEA compared to …

MaleVascular Endothelial Growth Factor AIntegrinsBiophysicsNeovascularization PhysiologicBioengineeringpoly(ethyl acrylate)ArticleBiomaterialsHuman Umbilical Vein Endothelial CellsImage Processing Computer-AssistedAnimalsHumansPhosphorylationExtracellular Signal-Regulated MAP KinasesFibronectinTissue EngineeringPhospholipase C gammaProtein assemblyVascularizationVEGFFibronectinsMice Inbred C57BLCellular MicroenvironmentMechanics of MaterialsFocal Adhesion Protein-Tyrosine KinasesFISICA APLICADAMutationCeramics and CompositesINGENIERIA ELECTRICAGrowth factorsProtein BindingSignal Transduction
researchProduct

Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice

2003

Angiogenesis is crucial to tumor growth and metastasis, and interruption of this process is a prime avenue for therapeutic intervention of tumor proliferation. The present study has made use of the S180 tumor-bearing mouse model to investigate the polysaccharopeptide, PSP, isolated from the edible mushroom Coriolus versicolor, a herbal medicine known for its anti-angiogenesis properties. Quantitative analysis of microcorrosion casting of the tumor tissue showed more angiogenic features such as dense sinusoids and hot spots, in control (untreated) than in PSP-treated animals. Immunostaining of tumor tissues with antibody against the endothelial cell marker (Factor VIII) demonstrated a positi…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAngiogenesisDrinkingAdministration OralBiologyCorrosion CastingGeneral Biochemistry Genetics and Molecular BiologyMetastasisNeovascularizationMiceImage Processing Computer-AssistedmedicineAnimalsRNA MessengerRNA NeoplasmGeneral Pharmacology Toxicology and PharmaceuticsFluorescent Antibody Technique IndirectMice Inbred BALB CNeovascularization PathologicReverse Transcriptase Polymerase Chain ReactionBasidiomycotaWaterGeneral Medicinemedicine.diseaseAntineoplastic Agents PhytogenicEndothelial stem cellDisease Models AnimalVascular endothelial growth factor AMicroscopy Electron Scanningbiology.proteinBlood VesselsProteoglycansSarcoma ExperimentalSarcomamedicine.symptomAntibodyNeoplasm TransplantationImmunostainingLife Sciences
researchProduct

Angiogenesis in oral lichen planus: an in vivo and immunohistological evaluation.

2010

Oral lichen planus (OLP) is an autoimmune disease with an inflammatory pathogenesis. The angiogenetic phenomenon is a mechanism at the base of the pathogenesis of chronic inflammatory processes. The aim of this research is to evaluate the angiogenetic phenomenon, comparing an in vitro method with an in vivo one. Thirty OLP patients and 30 healthy subjects were enrolled in the study. Immunohistochemical analysis of the vascular-endothelial growth factor (VEGF) and vascular-endothelial adhesion molecules were carried out by the means of primary antibodies and anti-CD34, anti-VEGF, anti-CD106 antigen (VCAM-1) and anti-CD54 antigen (ICAM-1). Capillary density and others capillaroscopic paramete…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAngiogenesisImmunologyBiologyMicroscopic AngioscopyPathogenesisNeovascularizationchemistry.chemical_compoundstomatognathic systemIn vivoSettore MED/28 - Malattie OdontostomatologichemedicineImmunology and AllergyHumansOral mucosaangiogenesis Videocapillaroscopy VEGF ImmunohistochemistryAutoimmune diseaseNeovascularization PathologicGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCapillariesVascular endothelial growth factorstomatognathic diseasesmedicine.anatomical_structurechemistryCase-Control StudiesOral lichen planusFemalemedicine.symptomCell Adhesion MoleculesLichen Planus OralArchivum immunologiae et therapiae experimentalis
researchProduct

Angiogenesis in Wounds Treated by Microdeformational Wound Therapy.

2011

BACKGROUND:: Mechanical forces play an important role in tissue neovascularization and are a constituent part of modern wound therapies. The mechanisms by which vacuum assisted closure (VAC) modulates wound angiogenesis are still largely unknown. OBJECTIVE:: To investigate how VAC treatment affects wound hypoxia and related profiles of angiogenic factors as well as to identify the anatomical characteristics of the resultant, newly formed vessels. METHODS:: Wound neovascularization was evaluated by morphometric analysis of CD31-stained wound cross-sections as well as by corrosion casting analysis. Wound hypoxia and mRNA expression of HIF-1α and associated angiogenic factors were evaluated by…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyWound therapyAngiogenesismedicine.medical_treatmentNeovascularization PhysiologicOcclusive DressingsArticleNeovascularizationMiceNegative-pressure wound therapymedicineAnimalsSkinWound Healingintegumentary systemReverse Transcriptase Polymerase Chain Reactionbusiness.industryGranulation tissueBiomechanical PhenomenaMice Inbred C57BLOxygenPlatelet Endothelial Cell Adhesion Molecule-1Occlusive dressingVascular endothelial growth factor Amedicine.anatomical_structureMicrovesselsGranulation TissueCancer researchSurgerymedicine.symptombusinessWound healingNegative-Pressure Wound Therapy
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Atrial fibrillation is associated with cardiac hypoxia.

2008

BACKGROUND: Atrial fibrillation (AF), the most common human arrhythmia, is responsible for substantial morbidity and mortality and may be promoted by selective atrial ischemia and atrial fibrosis. Consequently, we investigated markers for hypoxia and angiogenesis in AF. METHODS: Right atrial appendages (n=158) were grouped according to heart rhythm [sinus rhythm (SR) or AF]. The degree of fibrosis and microvessel density of all patients were determined morphometrically using Sirius-Red- and CD34/CD105-stained sections, respectively. Next, sections (n=77) underwent immunostaining to detect hypoxia- and angiogenesis-related proteins [hypoxia-inducible factor (HIF)1 alpha, HIF2 alpha, vascular…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyCytoplasmAngiogenesisIschemiaMyocardial IschemiaBiologyPathology and Forensic Medicinechemistry.chemical_compoundFibrosisInternal medicineAtrial FibrillationmedicineBasic Helix-Loop-Helix Transcription FactorsHumansSinus rhythmAtrial AppendageHypoxiaMicrovesselAgedCell NucleusNeovascularization PathologicMicrocirculationMyocardiumAtrial fibrillationGeneral MedicineHypoxia (medical)Middle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCoronary VesselsFibrosisUp-RegulationVascular endothelial growth factorEndocrinologychemistryCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicineBiomarkersCardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
researchProduct

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Colla…

2014

Purpose: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. Methods: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). Results: There were 24 girls and 15 boys with group median age of 13 years (range, 3–17 years). Mean follow-up period was 12.8 months (range, 3–60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabAdolescentVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedOphthalmologyRanibizumabmedicineHumansChildRetrospective StudiesRetinabusiness.industryRetrospective cohort studyGeneral Medicineeye diseasesChoroidal NeovascularizationClinical trialBevacizumabOphthalmologyChoroidal neovascularizationmedicine.anatomical_structureTreatment OutcomeChild PreschoolIntravitreal InjectionsEtiologyFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct